Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers (2019–2023)

We evaluated the antimicrobial susceptibility of 1,400 clinical isolates of Stenotrophomonas maltophilia consecutively collected from United States medical centers in 2019-2023. Aztreonam-avibactam (MIC50/90, 2/4 µg/mL; 99.6% inhibited at ≤8 µg/mL) was the most active compound, followed by trimethoprim-sulfamethoxazole (MIC50/90, ≤0.12/0.5 µg/mL; 96.9% susceptible), minocycline (MIC50/90, 0.5/2 µg/mL; 89.2% susceptible), and levofloxacin (MIC50/90, 1/8 µg/mL; 78.9% susceptible). Aztreonam-avibactam retained potent activity against isolates not susceptible to trimethoprim-sulfamethoxazole, minocycline, and/or levofloxacin (99.3%-100.0% inhibited at ≤8 µg/mL).